We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts (MDRX) Collaborates With Microsoft, Shares Up
Read MoreHide Full Article
Allscripts Healthcare Solutions Inc. (MDRX - Free Report) recently collaborated with Microsoft Corporation (MSFT - Free Report) to explore an innovative technology for enhancing clinical research design, clinical studies and improving research process. For investors’ notice, the companies will now aim at extending Allscripts’ cloud-based electronic health record (EHR) platforms with new technologies.
Since the announcement of the collaboration, this Zacks Rank #4 (Sell) company witnessed a 5.5% increase in its share price to close at $11.02 yesterday.
Microsoft Signs MoU With Allscripts’ Veradigm
In a bid to develop an integrated research model through point-of-care technology platforms, Allscripts’ Veradigm has signed a memorandum of understanding (MoU) with Microsoft. Notably, Veradigm is the company’s payer and life sciences-focused business unit. Per the deal, both the companies are likely to conduct pilot programs for developing the compliance framework necessary to support research performed within this new operating model.
This latest collaboration will enable Allscripts to leverage on Microsoft’s exclusive solutions that are powered by Microsoft Azure and AI. Per management, this will help biopharmaceutical and clinical research organizations better conduct research.
More About Veradigm
Last November, Allscripts announced Veradigm as the new branding for Allscripts’ Payer & Life Sciences division. Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media.
Since the introduction of Veradigm, share prices of Allscripts increased 11.3% till date. However, the stock has lost 26.9% compared with the industry's 19.4% decline and S&P 500's 7% decrease in a year’s time.
A Sneak Peek at Allscripts Flagship EHRs
We believe that the Sunrise and Paragon EHR platforms are Allscripts’ major growth drivers. For investors’ notice, Allscripts Sunrise is a fully integrated EHR platform that connects all clinical and financial aspects of a hospital or health system for inpatient, emergency and outpatient care. Meanwhile, Paragon is an integrated EHR and financial/administrative solution for smaller hospitals serving a single IDN and community facilities. The company’s EHR diagnostic tools, including dbMotion, EPSi, FollowMyHealth and 2bPrecise, have been experiencing an increasing list of clients outside the company’s EHR base.
In the third quarter of 2018, Allscripts witnessed a number of contract extensions across both the Sunrise and Paragon customers. For example, the company signed a seven-year extension for Sunrise Clinicals, including the addition of Sunrise Registration and Scheduling modules at the Hospital for Special Care in New Britain, CT. Allscripts also signed a five-year managed services expansion agreement with South Nassau Communities Hospital on Long Island, New York.
Veeva Systems’ long-term earnings growth rate is projected at 19.5%.
Penumbra has a long-term earnings growth rate of 20%.
OPKO Health’s long-term earnings growth rate is projected at 12%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Allscripts (MDRX) Collaborates With Microsoft, Shares Up
Allscripts Healthcare Solutions Inc. (MDRX - Free Report) recently collaborated with Microsoft Corporation (MSFT - Free Report) to explore an innovative technology for enhancing clinical research design, clinical studies and improving research process. For investors’ notice, the companies will now aim at extending Allscripts’ cloud-based electronic health record (EHR) platforms with new technologies.
Since the announcement of the collaboration, this Zacks Rank #4 (Sell) company witnessed a 5.5% increase in its share price to close at $11.02 yesterday.
Microsoft Signs MoU With Allscripts’ Veradigm
In a bid to develop an integrated research model through point-of-care technology platforms, Allscripts’ Veradigm has signed a memorandum of understanding (MoU) with Microsoft. Notably, Veradigm is the company’s payer and life sciences-focused business unit. Per the deal, both the companies are likely to conduct pilot programs for developing the compliance framework necessary to support research performed within this new operating model.
This latest collaboration will enable Allscripts to leverage on Microsoft’s exclusive solutions that are powered by Microsoft Azure and AI. Per management, this will help biopharmaceutical and clinical research organizations better conduct research.
More About Veradigm
Last November, Allscripts announced Veradigm as the new branding for Allscripts’ Payer & Life Sciences division. Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media.
Since the introduction of Veradigm, share prices of Allscripts increased 11.3% till date. However, the stock has lost 26.9% compared with the industry's 19.4% decline and S&P 500's 7% decrease in a year’s time.
A Sneak Peek at Allscripts Flagship EHRs
We believe that the Sunrise and Paragon EHR platforms are Allscripts’ major growth drivers. For investors’ notice, Allscripts Sunrise is a fully integrated EHR platform that connects all clinical and financial aspects of a hospital or health system for inpatient, emergency and outpatient care. Meanwhile, Paragon is an integrated EHR and financial/administrative solution for smaller hospitals serving a single IDN and community facilities. The company’s EHR diagnostic tools, including dbMotion, EPSi, FollowMyHealth and 2bPrecise, have been experiencing an increasing list of clients outside the company’s EHR base.
In the third quarter of 2018, Allscripts witnessed a number of contract extensions across both the Sunrise and Paragon customers. For example, the company signed a seven-year extension for Sunrise Clinicals, including the addition of Sunrise Registration and Scheduling modules at the Hospital for Special Care in New Britain, CT. Allscripts also signed a five-year managed services expansion agreement with South Nassau Communities Hospital on Long Island, New York.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Veeva Systems Inc (VEEV - Free Report) , Penumbra, Inc. (PEN - Free Report) and OPKO Health, Inc (OPK - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Veeva Systems’ long-term earnings growth rate is projected at 19.5%.
Penumbra has a long-term earnings growth rate of 20%.
OPKO Health’s long-term earnings growth rate is projected at 12%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>